Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02028325 · ClinicalTrials.gov registry record · Phase 4
Yellow 560 Microscope for Intraoperative Visualization of Fluorescein Stained Intracranial Lesions
A Phase 4 study, sponsored by Indiana University.
- Terminated
- Registry status
- Phase 4
- Development phase
- 136
- Enrollment target
NCT02028325: Clinical Trial Phase 4 study, sponsored by Indiana University.
NCT02028325 is a Phase 4 study that was terminated before completion, run by Indiana University. The registered enrollment target is 136 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (74% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02028325, a Phase 4 study, was terminated before completion, sponsored by Indiana University.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 136 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the effectiveness of using Fluorescein Sodium and the Yellow 560 microscope to aid in treatment of intracranial tumors and vascular lesions.
Primary Outcome
We will perform fluorescein fluorescence/angiography at surgery and assess if fluorescence reveals any residual tumor or vascular lesion (aneurysm, arteriovenous malformation, or arteriovenous fistula) following surgical intervention. For subjects with brain tumors we will then perform a regular postoperative MRI and assess if there was any residual tumor and measure the accuracy of fluorescein fluorescence to assess the amount of the residual tumor seen on the postoperative MRI. Similarly, for
Interventions
- DRUG Fluorescein Sodium
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 136 participants |
| Start Date | 2013-12 |
| Est. Completion | 2016-10 |
| Phase | Phase 4 |
Why NCT02028325 stopped before completion
NCT02028325 is an interventional study that assigns participants to a tested intervention. The registered 136 participants enrollment target is mid-sized for trials with a published cap, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (74% lower).
The record links to 0 conditions, and to 1 intervention - of which Fluorescein Sodium is the first listed.
NCT02028325 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02028325 about?
NCT02028325 is a clinical study titled "Yellow 560 Microscope for Intraoperative Visualization of Fluorescein Stained Intracranial Lesions". The purpose of this study is to evaluate the effectiveness of using Fluorescein Sodium and the Yellow 560 microscope to aid in treatment of intracranial tumors and vascular lesions.
What is the current status of trial NCT02028325?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 136 participants. The study started on 2013-12. Estimated completion is 2016-10.
What interventions are being tested in trial NCT02028325?
The interventions under investigation include: Fluorescein Sodium (DRUG).
Who is sponsoring clinical trial NCT02028325?
This trial is sponsored by Indiana University, which has 890 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02028325's enrollment target sits among peer trials
136 596th of 2000 higher than 1,400 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01555892 · 136 participants · Phase 1
Cytotoxic T-Lymphocytes for EBV-positive Lymphoma, GRALE
- NCT03216525 · 136 participants · Phase 3
Alvimopan Versus Placebo in Patients Undergoing Radical Cystectomy on an Enhanced Recovery Protocol
- NCT04476901 · 136 participants · Phase 2
Administration of Allogeneic-MSC in Patients With Non-Ischemic Dilated Cardiomyopathy
- NCT04603898 · 136 participants · NA
Oxalate Formation From Ascorbic Acid
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia